Essex LLC Purchases New Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Essex LLC purchased a new position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 788 shares of the biopharmaceutical company's stock, valued at approximately $213,000.

A number of other institutional investors and hedge funds have also recently modified their holdings of ALNY. Capital World Investors grew its stake in Alnylam Pharmaceuticals by 0.6% in the 4th quarter. Capital World Investors now owns 16,600,525 shares of the biopharmaceutical company's stock worth $3,906,284,000 after acquiring an additional 92,101 shares in the last quarter. Vanguard Group Inc. boosted its holdings in shares of Alnylam Pharmaceuticals by 0.8% in the fourth quarter. Vanguard Group Inc. now owns 12,733,399 shares of the biopharmaceutical company's stock valued at $2,996,296,000 after purchasing an additional 98,303 shares during the period. Capital Research Global Investors boosted its holdings in shares of Alnylam Pharmaceuticals by 32.9% in the fourth quarter. Capital Research Global Investors now owns 6,968,513 shares of the biopharmaceutical company's stock valued at $1,639,767,000 after purchasing an additional 1,724,610 shares during the period. Regeneron Pharmaceuticals Inc. bought a new position in Alnylam Pharmaceuticals in the fourth quarter worth approximately $1,045,822,000. Finally, T. Rowe Price Investment Management Inc. increased its holdings in Alnylam Pharmaceuticals by 39.7% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 4,384,449 shares of the biopharmaceutical company's stock worth $1,031,705,000 after purchasing an additional 1,245,195 shares during the period. 92.97% of the stock is owned by institutional investors.

Insider Transactions at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, CEO Yvonne Greenstreet sold 31,640 shares of the business's stock in a transaction dated Friday, May 30th. The stock was sold at an average price of $304.39, for a total transaction of $9,630,899.60. Following the sale, the chief executive officer owned 48,948 shares in the company, valued at approximately $14,899,281.72. The trade was a 39.26% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 1.50% of the stock is owned by company insiders.

Alnylam Pharmaceuticals Stock Up 0.7%

Shares of ALNY stock traded up $2.17 during trading hours on Thursday, reaching $331.94. 431,157 shares of the company's stock were exchanged, compared to its average volume of 853,986. Alnylam Pharmaceuticals, Inc. has a 1 year low of $205.87 and a 1 year high of $334.13. The company has a current ratio of 3.04, a quick ratio of 2.98 and a debt-to-equity ratio of 8.88. The stock has a market cap of $43.28 billion, a PE ratio of -158.82 and a beta of 0.23. The stock's fifty day moving average price is $291.57 and its two-hundred day moving average price is $264.87.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last released its earnings results on Thursday, May 1st. The biopharmaceutical company reported ($0.44) earnings per share for the quarter, missing the consensus estimate of ($0.37) by ($0.07). The company had revenue of $594.19 million for the quarter, compared to analysts' expectations of $584.32 million. Alnylam Pharmaceuticals had a negative return on equity of 510.31% and a negative net margin of 11.49%. The firm's revenue for the quarter was up 20.2% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.16) EPS. Research analysts predict that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current year.

Analyst Upgrades and Downgrades

Several brokerages have weighed in on ALNY. Wells Fargo & Company upped their target price on Alnylam Pharmaceuticals from $287.00 to $333.00 and gave the stock an "equal weight" rating in a report on Monday. Citigroup upped their price objective on shares of Alnylam Pharmaceuticals from $338.00 to $351.00 and gave the stock a "buy" rating in a research note on Friday, March 21st. BMO Capital Markets increased their target price on shares of Alnylam Pharmaceuticals from $300.00 to $360.00 and gave the stock an "outperform" rating in a report on Tuesday, June 24th. UBS Group boosted their price target on shares of Alnylam Pharmaceuticals from $331.00 to $349.00 and gave the company a "buy" rating in a report on Friday, May 2nd. Finally, Canaccord Genuity Group increased their price objective on shares of Alnylam Pharmaceuticals from $385.00 to $390.00 and gave the company a "buy" rating in a research note on Friday, March 21st. One investment analyst has rated the stock with a sell rating, four have given a hold rating and twenty have issued a buy rating to the company. According to MarketBeat, Alnylam Pharmaceuticals presently has a consensus rating of "Moderate Buy" and a consensus price target of $340.00.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.